New Directions in Chemotherapy-Induced Neutropenia

Lee Schwartzberg, MD, FACP, of the West Cancer Center, highlights variables that increase the risk for developing chemotherapy-induced neutropenia and its implications on patients.

An overview of the impact of chemotherapy-induced neutropenia on the selection, dosage, and utilization of chemotherapy.

A clinician’s recommendations for appropriately monitoring patients with cancer for chemotherapy-induced neutropenia or other infections.

Suggestions regarding when it is appropriate to initiate chemotherapy-induced neutropenia prophylaxis in patients with cancer and goals of therapy.

A historical overview regarding the development and role of granulocyte colony-stimulating factors as prophylaxis for chemotherapy-induced neutropenia and recommendations for use.

Limitations and other factors to consider when utilizing granulocyte colony-stimulating factors as prophylaxis for chemotherapy-induced neutropenia.

Lee Schwartzberg, MD, FACP, of the West Cancer Center, highlights exciting data demonstrated by PROTECTIVE-2 study of plinabulin with pegfilgrastim as prevention of chemotherapy-induced neutropenia and implications for using the combination in the future.

Best practices for treating patients with cancer who are receiving chemotherapy to reduce the risk for chemotherapy-induced neutropenia during the COVID-19 pandemic, as recommended by modified NCCN guidelines.

A payer remarks on the costs of chemotherapy-induced neutropenia (CIN) on the health system and shares thoughts on the utilization of newer therapies and delivery of CIN prophylaxis to appropriate patients.

To address the impact of chemotherapy-induced neutropenia on the delivery of chemotherapy to patients, Dr John Fox discusses how health plans are best supporting members.

How newer therapies are reducing cancer patients’ risk of developing chemotherapy-induced neutropenia and the need for prophylaxis.

The pros and cons of at-home administration of granulocyte-colony-stimulating factors as treatment for chemotherapy-induced neutropenia prophylaxis, and programs organized by payers to best support members.

The impact of the COVID-19 pandemic on oncology practices, especially those operating under the Oncology Care Model, regarding the management of chemotherapy-induced neutropenia, and reactions by payers.